Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects

Internal Medicine

Volumn 41, Issue 10, 2002, Pages 793-797

  Hamada, Toshihiro ^a,b   Hisatome, Ichiro ^a,b   Kinugasa, Yoshiharu ^a,b   Matsubara, Koichi ^a,b   Shimizu, Hideki ^a,b   Tanaka, Hiroaki ^a,b   Furuse, Masako ^a,b   Sonoyama, Kazuhiko ^a,b   Yamamoto, Yasutaka ^a,b   Ohtahara, Akira ^a,b   Igawa, Osamu ^a,b   Shigemasa, Chiaki ^a,b   Yamamoto, Tetsuya ^a,b  

^a TOTTORI UNIVERSITY HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Antihypertensive agents; Healthy volunteers; Urate metabolites; Urinary excretion

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ENALAPRIL; HYPOXANTHINE; LOSARTAN; PURINE DERIVATIVE; URIC ACID; XANTHINE;

ADULT; ANION EXCHANGE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; NUCLEIC ACID METABOLISM; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 0036807830     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.793     Document Type: Article

References (14)

1. Leary WP, Reyes AJ, Acosta-Barrios TN, Maharaj B. Captopril once daily as monotherapy in patients with hyperuricemia and essential hypertension. Lancet 1: 1277, 1985 (letter).
2. Navis GJ, DeLong PE, DeZeeuw D. Serum uric acid, ACE inhibitors and natriuresis. Lancet 2: 156, 1985 (letter).
3. Faulds D, Sorkin EM. Ferodipine.A review of the pharmacology and therapeutic use of the extended release formulation in older patients. Drugs Aging 2: 374-388, 1992.
4. Iimura O, Shimamoto K. Efficacy and mode of action of manidipine: a new calcium channel antagonist. Am Heart J 125 (2 pt 2): 635-641, 1993.
5. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42: 333-335, 1992.
6. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 49: 1787-1790, 1996.
7. Edwards RM, Trizna W, Stack EJ, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 276: 125-129, 1996.
8. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Fe R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 17: 1033-1039, 1999.
9. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 280: 839-845, 1997.
10. Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 7: 1035-1040, 1994.
11. Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP. Renal effects of angiotensin I -receptor blockade and angiotensin convertase inhibition in man. Clin Sci 90: 205-213, 1996.
12. Tikkanen I, Omvik P, Jansen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 13: 1343-1351, 1995.
13. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J Rheumatol 27: 2232-2236, 2000.
14. Yamamoto T, Moriwaki Y, Takahashi S, Hada T, Higashino K. Renal excretion of purine bases. Effects of probenecid, benzbromarone and pyrazinamide. Nephron 48: 116-120, 1988.